EVFM Evofem Biosciences Inc.

3.54
-0.31  -8%
Previous Close 3.85
Open 3.82
Price To Book -9.08
Market Cap 91557124
Shares 25,867,248
Volume 12,999
Short Ratio
Av. Daily Volume 29,239

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b/3 commencement of enrollment announced January 23, 2018.
Amphora - AMPREVENCE
Prevention of urogenital Chlamydia trachomatis infection in women
Phase 3 data due late-2018.
Amphora - AMPOWER
contraceptive vaginal gel

Latest News

  1. Evofem Biosciences to Present at Piper Jaffray Healthcare Conference on November 27, 2018
  2. Edited Transcript of EVFM earnings conference call or presentation 7-Nov-18 4:00pm GMT
  3. Evofem Biosciences Completes Phase 3 Clinical Trial of Amphora for Prevention of Pregnancy
  4. Evofem Biosciences Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  5. Evofem Biosciences to Host Key Opinion Leader Event: New Perspectives in Birth Control--Non-Hormonal, On Demand and Woman Controlled
  6. Evofem Biosciences to Report Third Quarter 2018 Results on November 7, 2018
  7. Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society of Reproductive Medicine Annual Congress
  8. Survey Reveals High Number of Sexually Active Women Who Use No Birth Control Method, Supporting the Continued Need for Non-Hormonal Birth Control Innovations such as Evofem Biosciences' Product Candidate Amphora®
  9. New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine (ASRM) Annual Congress
  10. Evofem Biosciences to Present at Upcoming Investor Conferences
  11. 3 Small Biotech Stocks That Almost Doubled in Past Month
  12. Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora®, for the Prevention of Chlamydia
  13. Evofem Biosciences to Present at 20th Annual Global Investment Conference on September 6, 2018
  14. Evofem Biosciences' Chief Medical Officer, Dr. Kelly Culwell, to Present at #BlogHer18 Creators Summit
  15. Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
  16. Evofem Biosciences to Report Second Quarter 2018 Results and Provide Corporate Update on August 2, 2018
  17. Should You Be Concerned About Evofem Biosciences Inc’s (NASDAQ:EVFM) Shareholders?
  18. Evofem Biosciences to Present at Jefferies Global Healthcare Conference on June 7, 2018
  19. Evofem Biosciences Announces Closing of Public Offering of Common Stock and Warrants
  20. Evofem Biosciences Announces Pricing of Public Offering of Common Stock and Warrants